Axogen Inc (AXGN) Stock Price, Quote & News

Company Profile

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wra...

Industry: Medical Devices

Sector: Healthcare

Phone: 386 462 6800

Fax: 386 462 6801

Website: www.axogeninc.com

Address:

13631 Progress Boulevard, Suite 400, Alachua, United States

dustin1101 May. 14 at 6:53 PM

$AXGN As you can see, doesn't take much to move this up. Smart/big $$ still lurking out there.

0 · Reply

MarketBeat May. 14 at 3:08 PM

https://marketbeat.com/a/8654727/ $AXGN AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam

0 · Reply

NVDAMillionaire May. 14 at 7:08 AM

$AXGN Outstanding article that hits the mark on AXGN's current state. So if you want to refresh your AXGN insights or learn about AXGN from scratch, this is a must read. https://everyticker.com/quote/AXGN/analysis/axogen-s-biologic-monopoly-how-12-years-of-fda-exclusivity-is-transforming-a-niche-device-maker-into-a-cash-generating-standard-of-care-nasdaq-axgn

0 · Reply

dustin1101 May. 13 at 7:33 PM

$AXGN the sellers down here will get left in the dust soon IMO.. just like the ones at $35, the low 30s etc etc etc...

0 · Reply

dustin1101 May. 11 at 2:50 PM

$AXGN Def getting knocked down by more insider sales but I bet they’re almost done. Mkt is strong. Adding here.

0 · Reply

dustin1101 May. 8 at 6:56 PM

$AXGN I’m betting $ this is down on planned insider sales hitting the tape indiscriminately. This has happened in quarters past post ER and when they’re done it floats back up.

0 · Reply

dustin1101 May. 6 at 2:11 PM

$AXGN you can always count on these discount sellers to reload what you trim into a strong close. lol

0 · Reply

dustin1101 May. 5 at 2:55 PM

$AXGN shorts under pressure across many squeezy names this morning. They seem to be a little nervous here after pushing down to a .618 test and now right back up to .382.. So thin, $44.50 lets go.

0 · Reply

dustin1101 May. 4 at 4:11 PM

$AXGN might catch a bid with bio sector standing out today. We'll see, stuck under the .5 fib now.

0 · Reply

dustin1101 May. 4 at 1:46 PM

$AXGN Respecting fib levels pretty well. In a range between 50% (42.70) and 38.2% (43.50) levels on the ER move. Next level up is 23.6% or approx $44.50. Watch the mkt. 61.8% is stronger support at just below $42.

0 · Reply

Axogen Transcript: Bank of America Global Healthcare Conference 2026

Apr 30, 2026, 7:00 AM EDT - 15 days ago

Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference

2026-04-29T16:57:39.000Z - 16 days ago

AxoGen price target raised to $48 from $41 at Raymond James

2026-04-29T13:02:40.000Z - 16 days ago

AxoGen price target raised to $50 from $45 at Canaccord

2026-04-29T10:16:26.000Z - 16 days ago

AxoGen price target raised to $50 from $39 at H.C. Wainwright

2026-04-29T09:53:29.000Z - 16 days ago

AxoGen price target raised to $50 from $42 at Citizens

2026-04-28T14:28:46.000Z - 17 days ago

AxoGen rises 12.8%

Apr 28, 2026, 8:00 AM EDT - 17 days ago

Axogen Earnings Call Transcript: Q1 2026

2026-04-28T11:49:44.000Z - 17 days ago

AxoGen raises FY26 revenue view to $270M from $265.7M, consensus $265.89M

2026-04-28T11:08:24.000Z - 17 days ago

AxoGen reports Q1 adjusted EPS 7c, consensus 7c

Apr 28, 2026, 7:00 AM EDT - 17 days ago

Axogen, Inc. Reports First Quarter 2026 Financial Results

2026-04-24T11:16:41.000Z - 21 days ago

AxoGen price target raised to $45 from $40 at Canaccord

2026-04-23T12:44:20.000Z - 22 days ago

AxoGen price target raised to $50 from $40 at Lake Street

2026-04-16T20:00:22.000Z - 4 weeks ago

AxoGen jumps after Cigna picks up Avance nerve graft

Apr 14, 2026, 7:00 AM EDT - 4 weeks ago

Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026

Mar 10, 2026, 12:30 PM EDT - 2 months ago

Axogen Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 1:00 PM EDT - 2 months ago

Axogen Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 3:25 PM EST - 2 months ago

Axogen Transcript: 47th Annual Raymond James Institutional Investor Conference

Feb 24, 2026, 8:00 AM EST - 2 months ago

Axogen Earnings Call Transcript: Q4 2025

2026-02-24T12:06:53.000Z - 2 months ago

AxoGen reports Q4 adjusted EPS 7c, consensus 10c

2026-02-24T12:05:30.000Z - 2 months ago

AxoGen sees FY26 revenue $265.7M, consensus $259.53M

2026-02-24T10:40:34.000Z - 2 months ago

AxoGen price target raised to $42 from $34 at Citizens

2026-02-23T14:45:11.000Z - 2 months ago

AxoGen price target raised to $41 from $36 at Raymond James

2026-02-19T10:55:34.000Z - 3 months ago

AxoGen initiated with an Overweight at Wells Fargo

Feb 17, 2026, 7:00 AM EST - 3 months ago

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

Feb 10, 2026, 7:00 AM EST - 3 months ago

Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

2026-01-22T13:46:34.000Z - 4 months ago

AxoGen 4M share Spot Secondary priced at $31.00

Jan 21, 2026, 11:18 PM EST - 4 months ago

Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock

2026-01-21T21:16:01.000Z - 4 months ago

AxoGen announces $85M common stock offering

Jan 21, 2026, 4:09 PM EST - 4 months ago

Axogen Announces Proposed Public Offering of Common Stock

2026-01-21T21:05:26.000Z - 4 months ago

AxoGen files automatic mixed securities shelf

2026-01-21T21:05:17.000Z - 4 months ago

AxoGen files automatic mixed securities shelf

Jan 15, 2026, 1:30 PM EST - 4 months ago

Axogen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 4 months ago

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Dec 3, 2025, 8:01 PM EST - 5 months ago

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

Dec 3, 2025, 6:53 PM EST - 5 months ago

FDA approves Axogen's nerve repair graft

Dec 2, 2025, 12:30 PM EST - 5 months ago

Axogen Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 11:30 AM EST - 6 months ago

Axogen Transcript: Jefferies London Healthcare Conference 2025

Oct 29, 2025, 8:00 AM EDT - 7 months ago

Axogen Earnings Call Transcript: Q3 2025

Oct 29, 2025, 7:00 AM EDT - 7 months ago

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Oct 1, 2025, 12:30 PM EDT - 8 months ago

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

Aug 25, 2025, 6:40 AM EDT - 9 months ago

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Axogen Earnings Call Transcript: Q2 2025

Jul 29, 2025, 4:10 PM EDT - 10 months ago

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 22, 2025, 4:05 PM EDT - 10 months ago

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Axogen Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Axogen Earnings Call Transcript: Q1 2025

May 8, 2025, 7:05 AM EDT - 1 year ago

Axogen, Inc. Reports 2025 First Quarter Financial Results

Apr 24, 2025, 8:04 AM EDT - 1 year ago

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Mar 4, 2025, 9:00 AM EST - 1 year ago

Axogen Transcript: Investor Day 2025

Feb 25, 2025, 8:00 AM EST - 1 year ago

Axogen Earnings Call Transcript: Q4 2024

Feb 25, 2025, 7:10 AM EST - 1 year ago

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Feb 11, 2025, 4:58 PM EST - 1 year ago

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Jan 10, 2025, 5:00 PM EST - 1 year ago

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2024, 8:00 AM EST - 1 year ago

Axogen Earnings Call Transcript: Q3 2024

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Axogen Earnings Call Transcript: Q2 2024

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Axogen, Inc. Announces New Leadership Appointments

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 1, 2024, 7:00 AM EDT - 2 years ago

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

May 29, 2024, 4:40 PM EDT - 2 years ago

Axogen Transcript: 2024 Leerink Partners Healthcare Crossroads Conference

May 28, 2024, 4:30 PM EDT - 2 years ago

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 2, 2024, 8:00 AM EDT - 2 years ago

Axogen Earnings Call Transcript: Q1 2024

May 2, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc Reports First Quarter 2024 Financial Results

Apr 29, 2024, 4:50 PM EDT - 2 years ago

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Apr 16, 2024, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Mar 5, 2024, 8:00 AM EST - 2 years ago

Axogen Earnings Call Transcript: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Feb 13, 2024, 4:30 PM EST - 2 years ago

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 2, 2024, 4:15 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jan 18, 2024, 5:00 PM EST - 2 years ago

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Jan 4, 2024, 4:45 PM EST - 2 years ago

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Jan 4, 2024, 4:40 PM EST - 2 years ago

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Jan 4, 2024, 4:35 PM EST - 2 years ago

Axogen Announces Promotions on Research and Development Team

Dec 26, 2023, 4:15 PM EST - 2 years ago

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Dec 6, 2023, 7:00 AM EST - 2 years ago

Axogen Announces Transition of Finance Team Leadership

Dec 1, 2023, 5:00 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 30, 2023, 8:50 AM EST - 2 years ago

Axogen Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 7, 2023, 8:00 AM EST - 2 years ago

Axogen Earnings Call Transcript: Q3 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Axogen, Inc. Reports 2023 Third Quarter Financial Results

Oct 18, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™

Aug 31, 2023, 7:00 AM EDT - 2 years ago

Axogen to Participate at Upcoming Investor Conferences

Aug 21, 2023, 7:00 AM EDT - 2 years ago

Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio

Aug 7, 2023, 4:30 PM EDT - 3 years ago

Axogen Earnings Call Transcript: Q2 2023

Aug 7, 2023, 4:01 PM EDT - 3 years ago

Axogen, Inc. Reports 2023 Second Quarter Financial Results

Jul 27, 2023, 7:00 AM EDT - 3 years ago

Axogen to Participate at Canaccord Genuity's 43rd Annual Growth Conference

dustin1101 May. 14 at 6:53 PM

$AXGN As you can see, doesn't take much to move this up. Smart/big $$ still lurking out there.

0 · Reply

MarketBeat May. 14 at 3:08 PM

https://marketbeat.com/a/8654727/ $AXGN AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam

0 · Reply

NVDAMillionaire May. 14 at 7:08 AM

0 · Reply

dustin1101 May. 13 at 7:33 PM

$AXGN the sellers down here will get left in the dust soon IMO.. just like the ones at $35, the low 30s etc etc etc...

0 · Reply

dustin1101 May. 11 at 2:50 PM

$AXGN Def getting knocked down by more insider sales but I bet they’re almost done. Mkt is strong. Adding here.

0 · Reply

dustin1101 May. 8 at 6:56 PM

$AXGN I’m betting $ this is down on planned insider sales hitting the tape indiscriminately. This has happened in quarters past post ER and when they’re done it floats back up.

0 · Reply

dustin1101 May. 6 at 2:11 PM

$AXGN you can always count on these discount sellers to reload what you trim into a strong close. lol

0 · Reply

dustin1101 May. 5 at 2:55 PM

$AXGN shorts under pressure across many squeezy names this morning. They seem to be a little nervous here after pushing down to a .618 test and now right back up to .382.. So thin, $44.50 lets go.

0 · Reply

dustin1101 May. 4 at 4:11 PM

$AXGN might catch a bid with bio sector standing out today. We'll see, stuck under the .5 fib now.

0 · Reply

dustin1101 May. 4 at 1:46 PM

0 · Reply

PenkeInvesting May. 1 at 11:11 AM

Fundamental analysis of $AXGN (Axogen, Inc.) based on financial data and reported results. #AXGN

1 · Reply

SuperGreenToday Apr. 30 at 10:03 PM

$AXGN Share Price: $43.21 Contract Selected: Oct 16, 2026 $45 Calls Buy Zone: $4.08 – $5.04 Target Zone: $6.54 – $8.00 Potential Upside: 51% ROI Time to Expiration: 168 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Pika_Capital Apr. 30 at 7:06 PM

$AXGN wow sold years ago and now they are back to $40S .

0 · Reply

LuckEtradER Apr. 30 at 2:20 PM

$AXGN what a beast

2 · Reply

dustin1101 Apr. 30 at 1:41 PM

$AXGN seeing a little rotation into bio this morning.. look at $XBI

0 · Reply

dustin1101 Apr. 29 at 5:14 PM

$AXGN my view.. you can either sell here and maybe reload a gap fill or a bit lower. Or hold until the buyers outweigh the sellers, as they have come to consistently over the past year. There's also always the risk of being out in the event of an acquisition or payer update. I'm holding/already reloaded the vast majority. GLTA.

1 · Reply

IN0V8 Apr. 29 at 3:53 PM

$AXGN Mizuho raises target price to $55 from $40 Raymond James raises target price to $48 from $41 H.C. Wainwright raises target price to $50 from $39 Wells Fargo raises target price to $48 from $40

0 · Reply

dustin1101 Apr. 29 at 12:20 PM

$AXGN Mizhuo $40 >> $55, Citizens $42 >> $50, HC Wainright $39 >> $50, Wells Fargo $40 >> $48, Raymond James $41 >> $48, Cannacord $45 >> $50,

0 · Reply

DARKP00L Apr. 29 at 11:57 AM

$AXGN 07:35 on Apr. 29 2026 HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $50 #tradeideas

0 · Reply

Quantumup Apr. 29 at 10:26 AM

Citizens⬆️ $AXGN's PT to $50 from $42 and reiterated at Market Outperform. $BAX $SYK IART MDGX Mizuho⬆️PT to $55 from $40 and reiterated at Outperform. Here's what Citizens and Mizuho had to say: https://x.com/Quantumup1/status/2049434277276758434?s=20

0 · Reply

WallStWingman Apr. 28 at 8:23 PM

Shaved some on the earnings beat this morning and now we trail the rest $AXGN

0 · Reply

dustin1101 Apr. 28 at 7:53 PM

$AXGN buying some EOD here. Looking forward to seeing new PT's $50+

0 · Reply

Market Cap	2.14B
Revenue (ttm)	225.21M
Net Income (ttm)	-15.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6.97%
Debt to Equity Ratio	0.01

Volume	1,029,042
Avg Vol	1,045,208
Day's Range	N/A - N/A
Shares Out	53.18M
Stochastic %K	29%
Beta	1.17
Analysts	Strong Sell
Price Target	$50.00